Inicio › Cáncer de esófago › Pensilvania › Pittsburgh
Ensayos clínicos de Cáncer de esófago en Pittsburgh, PA
15 estudios para Cáncer de esófago buscan participantes en centros de Pittsburgh y alrededores (a unos 30 millas). Abra un estudio para ver quién puede participar y cómo contactar con el equipo.
Texto oficial del estudio (inglés)
A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)
ReclutandoFase 1/2
- UPMC Hillman Cancer Center-UPMC ( Site 4904), Pittsburgh
Distance-Based Exercise to Preserve Function and Prevent Disability
Reclutando
- UPMC Hillman Cancer Center, Pittsburgh
A Study of LY4257496 in Participants With Cancer (OMNIRAY)
ReclutandoFase 1
- University of Pittsburgh Medical Center, Pittsburgh
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
ReclutandoFase 1/2
- Allegheny Health Network, Pittsburgh
SKL35501 With SKL35502 Imaging in Adults With NTSR1 Positive Advanced Solid Tumors
ReclutandoFase 1
- UPMC Hillman Cancer Center, Pittsburgh
Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2
ReclutandoFase 3
- Research Site, Pittsburgh
- Research Site, Pittsburgh
Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)
ReclutandoFase 1/2
- UPMC Hillman Cancer Center-UPMC ( Site 8904), Pittsburgh
Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)
ReclutandoFase 1/2
- UPMC Hillman Cancer Center-UPMC ( Site 6904), Pittsburgh
Lead-212 PSV359 Therapy for Patients With Solid Tumors
ReclutandoFase 1/2
- University of Pittsburgh Medical Center, Pittsburgh
Impact of Prehabilitation in Oncology Via Exercise- Esophageal (IMPROVE-Esophageal)
Reclutando
- UPMC Hillman Cancer Center, Pittsburgh
Patient Preference for Subcutaneous vs. Intravenous Immune Therapy
ReclutandoFase 2
- UPMC Hillman Cancer Center, Pittsburgh
Esophageal Cancer Risk Registry
ReclutandoEstudio observacional
- Department of Cardiothoracic Surgery, Pittsburgh
Outcomes After Esophagectomy With a Focus on Minimally Invasive Esophagectomy and Quality of Life
ReclutandoEstudio observacional
- University of Pittsburgh Medical Center - Department of Cardiothoracic Surgery, Pittsburgh
- UPMC - Hillman Cancer Center, Pittsburgh
The MOMENTUM Study: The Multiple Outcome Evaluation of Radiation Therapy Using the MR-Linac Study
ReclutandoEstudio observacional
- Allegheny Health Network, Pittsburgh
Intra-tumoral (IT) Injection of vvDD-hIL2-2-RG-1 for Metastatic Gastrointestinal and Peritoneal Tumors
ReclutandoFase 1
- AHN West Penn Hospital, Pittsburgh
Más información sobre Cáncer de esófago en MedlinePlus
Ensayos de Cáncer de esófago en otras ciudades
- Houston, TX36 estudios
- Boston, MA23 estudios
- New York City, NY22 estudios
- Nashville, TN19 estudios
- St. Louis, MO17 estudios
- Los Angeles, CA15 estudios
- Grand Rapids, MI14 estudios
- Baldwin Park, CA14 estudios
- Philadelphia, PA13 estudios
- San Antonio, TX12 estudios
- Rochester, MN11 estudios
- Chicago, IL11 estudios
Otros estudios en Pittsburgh
- Cáncer de pulmón de células no pequeñas48 estudios
- Cáncer (todos los tipos)41 estudios
- Cáncer de seno39 estudios
- Cáncer del colon y del recto32 estudios
- Cáncer metastásico31 estudios
- Melanoma31 estudios
- Cáncer de ovario30 estudios
- Cáncer de endometrio23 estudios
- Cáncer de próstata23 estudios
- Cáncer de pulmón23 estudios
- Carcinoma de células escamosas de cabeza y cuello22 estudios
- Accidente cerebrovascular22 estudios
De ClinicalTrials.gov, datos obtenidos el 6 oct 2026. Cada estudio establece sus propios criterios de elegibilidad; el equipo del estudio decide quién puede participar.